Further studies on the effect of oral doxantrazole on allergen-induced bronchospasm.
The protective effect of oral doxantrazole on allergen-induced bronchoconstriction in man has been tested in two different treatment schedules. A single administration of 200 mg or 400 mg doxantrazole did not result in significant protection for a group of 10 patients. Only two patients after 200 mg, and three patients after 400 mg received meaningful protection. A 14-day period of treatment with three times 400 mg doxantrazole per day had no significant different effect compared with placebo treatment on allergen-induced broncho-constriction.
D000284:Administration, Oral; D000485:Allergens; D001986:Bronchial Spasm / Q000188:drug therapy* / Q000209:etiology / Q000276:immunology; D001993:Bronchodilator Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D005541:Forced Expiratory Volume; D006801:Humans; D010919:Placebos; D013777:Tetrazoles / Q000627:therapeutic use; D013892:Thioxanthenes / Q000627:therapeutic use*
D000485:Allergens; D001993:Bronchodilator Agents; D010919:Placebos; D013777:Tetrazoles; D013892:Thioxanthenes